Format

Send to

Choose Destination
See comment in PubMed Commons below
Immunol Lett. 2005 Aug 15;100(1):21-8.

CD28 superagonists: mode of action and therapeutic potential.

Author information

  • 1Institute for Virology and Immunology, University of Würzburg, Versbacher Strasse 7, 97078 Würzburg, Germany. huenig@vim.uni-wuerzburg.de

Abstract

Some CD28-specific monoclonal antibodies (mAbs) have the surprising property to activate T-cells without the need for TCR ligation. This review summarizes the differences between these "superagonistic" and conventional CD28-specific mAbs with regard to binding specificity and signalling properties. Furthermore, the dramatic effects of in vivo application of CD28 superagonists with regard to the induction of regulatory T-cells and polyclonal T-cell expansion in lymphopenic settings are discussed under the aspect of potential therapeutic applications.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk